Novel PET/CT Image Processing Method Identifies Anthracycline Cardiotoxicity

Overview

This study presents a novel image processing tool for qualitative and quantitative analysis of myocardial metabolic activity using [18F]FDG PET/CT scans in lymphoma patients treated with anthracyclines. The method enables early detection of cardiotoxic effects by assessing myocardial glucose uptake patterns, potentially preceding functional decline detected by echocardiography.

Background

Anthracycline chemotherapy, while effective against malignancies such as Hodgkin and Non-Hodgkin lymphoma, is associated with cardiotoxicity leading to left ventricular dysfunction and heart failure. Current cardiotoxicity monitoring relies mainly on echocardiographic assessment of left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS), which have limitations in sensitivity and variability. [18F]FDG PET/CT imaging offers a metabolic perspective by measuring myocardial glucose uptake, which may detect early metabolic alterations before functional impairment occurs. However, myocardial uptake is influenced by multiple physiological factors, necessitating robust image processing and quantitative analysis methods.

Data Highlights

The study retrospectively analyzed [18F]FDG PET/CT scans from lymphoma patients receiving anthracycline chemotherapy, with scans acquired at staging, interim, and end-of-treatment timepoints. PET images were filtered to reduce noise and enhance left ventricular boundary delineation. The left ventricle was segmented using CT-based localization and manual correction, followed by standardized orientation along cardiac axes. Myocardial uptake was quantified using standardized uptake values (SUV) mapped onto polar representations of the myocardium, enabling detailed regional metabolic assessment.

Key Findings

• The image processing tool successfully segmented and oriented the left ventricle in PET/CT scans for quantitative myocardial metabolic analysis.
• Myocardial glucose uptake patterns were characterized, distinguishing physiological from pathological uptake based on regional SUV differences.
• Patients treated with anthracyclines showed altered myocardial uptake patterns consistent with early cardiotoxicity before detectable changes in LVEF.
• A decrease of less than 20% in septal uptake relative to the lateral wall was associated with cardiac dysfunction, supporting previous findings.
• The method accounts for confounding factors affecting myocardial glucose metabolism by standardizing acquisition protocols and image processing.

Clinical Implications

This novel PET/CT image processing approach provides a sensitive tool for early detection of anthracycline-induced cardiotoxicity by assessing myocardial metabolic alterations. It complements echocardiographic measures, potentially enabling earlier intervention to prevent progression to overt cardiac dysfunction. Incorporation of metabolic imaging into cardiotoxicity monitoring protocols may improve risk stratification and management of cancer patients receiving cardiotoxic chemotherapy.

Conclusion

The proposed image processing method enhances the utility of [18F]FDG PET/CT for detecting early myocardial metabolic changes indicative of anthracycline cardiotoxicity. This approach offers a promising adjunct to conventional cardiac monitoring, facilitating timely identification and management of chemotherapy-related cardiac injury.

References

1. Various Authors/Clinical Practice Guidelines/2016-2019 -- Cardiotoxicity Detection and Monitoring in Cancer Patients
2. Previous Studies/2016-2019 -- Myocardial Glucose Uptake and Anthracycline Cardiotoxicity
3. Image Processing Methodology/2010-2015 -- PET Image Filtering and LV Segmentation Techniques